Close Menu

NEW YORK (GenomeWeb) – Clearbridge BioMedics said today that it has registered its target cell enrichment device, the ClearCell FX1 system, as a Class I medical device with the US Food and Drug Administration.

ClearCell is a label-free, microfluidics-based liquid biopsy device that allows for the enrichment of target cells from blood. The system had previously been CE-marked for in vitro diagnostic use in Europe, and was available in China as a China FDA-approved device. It was commercially launched in 2015.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

The Washington Post reports on researchers' efforts to determine the effect of an increasingly common SARS-CoV-2 mutation.

Florida Politics reports Florida's law barring life, long-term care, and disability insurers from using genetic information in coverage decisions went into effect at the beginning of July.

A new analysis finds a link between popular media coverage of a scientific study and how often that paper is cited.

In Nature this week: CRISPR approaches to editing plant genomes, way to speed up DNA-PAINT, and more.